Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $2.1 billion.

  • Avidity Biosciences' Liabilities and Shareholders Equity rose 3007.35% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 4285.87%. This contributed to the annual value of $1.6 billion for FY2024, which is 14880.8% up from last year.
  • Per Avidity Biosciences' latest filing, its Liabilities and Shareholders Equity stood at $2.1 billion for Q3 2025, which was up 3007.35% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Liabilities and Shareholders Equity ranged from a high of $2.1 billion in Q3 2025 and a low of $290.5 million during Q2 2021
  • Its 5-year average for Liabilities and Shareholders Equity is $855.9 million, with a median of $614.0 million in 2023.
  • As far as peak fluctuations go, Avidity Biosciences' Liabilities and Shareholders Equity crashed by 1824.43% in 2021, and later surged by 18626.6% in 2024.
  • Quarter analysis of 5 years shows Avidity Biosciences' Liabilities and Shareholders Equity stood at $427.6 million in 2021, then skyrocketed by 49.4% to $638.8 million in 2022, then decreased by 1.6% to $628.6 million in 2023, then surged by 148.81% to $1.6 billion in 2024, then surged by 36.47% to $2.1 billion in 2025.
  • Its last three reported values are $2.1 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.5 billion during Q1 2025.